Abstract Adult-onset Still's disease (AOSD) is a rare systemic inXammatory disorder characterised by high spiking fever, an evanescent salmon pink rash and arthritis, frequently accompanied by sore throat, myalgias, lymphadenopathies, splenomegaly and neutrophilic leukocytosis. Aetiology is still unknown, however, it seems that an important role is played by various infectious agents, which would act as triggers in genetically predisposed hosts. Diagnosis is a clinical one and may be lengthy because it requires exclusion of infectious neoplasms, including malignant lymphomas and leukaemias, and other autoimmune diseases. DiVerent diagnostic or classiWcation criteria have been proposed, but not deWnitely accepted. There are no speciWc laboratory tests for AOSD, but they reXect the systemic inXammation: the ESR is consistently high, while the rheumatoid factors and antinuclear antibodies are negative. High serum ferritin levels associated with a low fraction of its glycosylated component are assessed as useful diagnostic and disease activity markers. The clinical course can be divided into three main patterns with diVerent prognoses: self-limited or monophasic, intermittent or polycyclic systemic and chronic articular pattern. Therapy includes non-steroidal anti-inXammatory drugs, corticosteroids and disease modifying anti-rheumatic drugs: biological agents have recently been introduced and they seem to be very promising not only for the treatment but also for understanding the pathogenic mechanisms underlying the disease.
Introduction
Adult-onset Still's disease (AOSD) is a rare systemic inXammatory disorder of unknown aetiology, characterised by spiking fever, usually exceeding 39°C, an evanescent salmon pink rash, arthritis and multiorgan involvement [1, 2] . The disorder owes its name to Sir George Frederick Still, who, in 1897, described 22 children with symptoms consistent with what is currently known as systemic onset juvenile idiopathic arthritis [3] . AOSD was established as an autonomous disease entity almost a century later, when Eric Bywaters described 14 adults patients presenting symptoms similar to those seen in paediatric Still's disease [4] .
Epidemiology
Nowadays there is no agreement on the incidence and prevalence of the disease in diVerent populations: AOSD occurs worldwide and women barely seem to be aVected more often than men. AOSD usually aVects young people, with 75% of the cases reporting disease onset between 16 and 35 years of age [5] . Nevertheless, onset of AOSD after the age of 60 has been described in some cases [6] . The incidence in the Brittany and Loire regions of France has been assessed at 0.16 per 100,000 persons. The mean age of the study population was 36 years, with two peaks of distribution, respectively, at 15-25 and 36-45 years [7] . In a Dutch study of 45 patients, women were 60% and the median age of presentation was 25 years (range 16-65 years), with 27% of the patients showing onset of symptoms after the age of 35 [8] . An epidemiologic analysis from Japan evaluated the incidence amongst men at 0.22 per 100,000 inhabitants and at 0.34 per 100,000 amongst women [9] .
Etiopathogenesis
More than a century ago, Sir George Still reported that the aetiology of the disease he had described was "very uncertain" [3] . Uncertainty remains, but some progress has been made. Many studies evaluated a genetic predisposition, linking the disease with HLA antigens. In a retrospective survey of 62 patients from Canada, immunogenetic studies were executed on 55 of them, and HLA B17, B18, B35, and DR2 were signiWcantly associated with AOSD [10] . However, other studies failed to conWrm these claims and reported other associations, including HLA-B14 and DR7, or Bw35 and Cw4, or DR4 and Dw6 [11] . In summary, no consistent results have been obtained from association studies between AOSD and HLA loci. This may result from a real absence of an association or from heterogeneity of the disease. Besides, a familial tendency has not been reported.
A Japanese study evaluated polymorphisms of the interleukin (IL)-18 gene and discovered that the frequency of the diplotype conWguration of S01/S01 was signiWcantly higher in AOSD patients than in healthy control subjects [12] .
The constellation of abrupt onset, high fever, generalized adenopathy and leukocytosis suggest that AOSD may be a reactive syndrome, where a range of infectious agents trigger the disease in genetically predisposed hosts. These include viruses, such as rubella, CMV, EBV, human herpes virus 6, mumps, echovirus 7, parainXuenza, Coxsackievirus B4, adenovirus, inXuenza A, HBV, HCV and parvovirus B19, and others microbial agents like Mycoplasma pneumoniae, Chlamydia pneumoniae, Yersinia enterocolitica, Brucella abortus, and Borrelia burgdoferi [1, 13] .
Even abnormalities in cytokines production may play a pathophysiological role in AOSD. Patients with active, untreated AOSD seem to have a prevalence of Th1 cytokines in peripheral blood and tissues. The Th1 immune response increases production of IL-2, interferon (IFN) , and tumour necrosis factor (TNF) , cytokines that concur in activating macrophages and natural killer (NK) cells, leading B lymphocyte to the production of IgG2a subtype and promoting cell mediated immunity [14] .
Serum levels of IL-1, IL-6, IL-18, TNF , and IFN are considerably higher if compared with controls [10, 15, 16] .
High levels of IL-18 are observed in the acute phase of AOSD and this cytokine is considered to be the initiating factor for the inXammatory cascade that includes IFN , IL-6, and TNF . Over production of IL-1, TNF and IL-6 may account for symptoms observed in the disease and may provide possible therapeutic targets (Table 1) .
Unlike rheumatoid arthritis and systemic lupus erythematosus, hormonal inXuences do not seem to be considered important in AOSD. Pregnancy does not appear to be a risk factor for the development of the disease and does not increase the risk of relapses. Foetal outcomes are also normal in AOSD.
Clinical features
Adult-onset Still's disease may aVect several organs and it is worth recalling that the full constellation of symptoms may not be present at onset, and that the evolution to a "typical" case of AOSD may take several weeks or even months.
Fever, usually more than 39°C, is typically quotidian or double quotidian in pattern, with the highest temperatures seen in the late afternoon or early evening, and it is transient [8] . In particular, incidence of fever was estimated at about 95.7% according to Wve of the largest retrospective studies [8, 10, [18] [19] [20] . Fever usually precedes the onset of other manifestations and, in the majority of the cases, it represents the reason for which the patient addresses the physician.
The classic rash is an evanescent, salmon pink, macular or maculopapular eruption, which usually appears with the fever spike. The rash occurs in about 73% of patients, and it is predominantly found on the proximal limbs and trunk: it can be mildly pruritic (32% of the patients according to a Dutch study), and may be mistaken for a drug allergy. Histological Wndings show mild perivascular inXammation of the superWcial dermis with inWltration of lymphocytes and histiocytes [10, 19] . The typical Still's rash has only rarely been seen in other diseases, namely ulcerative colitis, vasculitis and leukaemia. However, the presence of atypical cutaneous manifestations does not have to exclude the suspicion of AOSD because several cases with atypical cutaneous manifestations have been described as well (Table 2) .
Arthralgia and arthritis occur in the majority of patients with AOSD, with incidences ranging from 64 to 100%. Arthritis may initially be mild, oligoarticular and transient, but it may evolve into a more severe, destructive, symmetrical and polyarticular form [19] over a period of several months., Joints usually involved are knees, wrists, and ankles, even though elbows, hips, shoulders, metacarpophalangeal and metatarso-phalangeal joints, proximal and distal interphalangeal joints and temporo-mandibular joints may be involved too [10, 19] . Acne-like lesions Ohta et al. [18] Cutaneous pain Ohta et al. [18] Eczematous lesions Ohta et al. [18] Toxic eruptions Ohta et al. [18] Alopecia Rowell and GoodWeld [22] Angioedema Soy [23] Erythema chronicum migrans Saito et al. [24] Persistent plaques and linear pigmentation Suzuki et al. [25] Non-caseating dermal granulomas Wissler [26] Fixed plaques Lubbe et al. [27] , Thien Huong et al. [28] , Kaur et al. [29] Urticaria SetterWeld et al. [30] , SalaY et al. [31] Vesiculopustules on the hands and feet Lee et al. [32] , Bachmeyer et al. [33] Generalized peau d'orange-like skin inWltration (diVuse cutaneous mucinosis)
Philips et al. [34] Persistent generalized erythema Fujii et al. [35] Useful signs for the diVerential diagnosis with rheumatoid arthritis, typically more frequent in cases of AOSD, are carpal and pericapitate abnormalities: changes in the wrist were described 6 months after disease onset with progressive joint space narrowing, especially in pericapitate or carpo-metacarpal regions: ankylosis may develop after 1.5-3 years [4] . During the initial acute phase of the disease, imaging is not helpful in establishing the diagnosis, but up to 41% of patients show a non-erosive intercarpal and carpometacarpal joint space narrowing of the wrist. Joint Xuid aspiration often reveals leucocytosis with a predominance of granulocyte polymorphonucleate [10, 19] .
Generalised myalgias, often rising with fever spikes, are usually found in the majority of patients with incidence ranging from 56 to 84% [8, 10, 18, 19] .
Liver abnormalities, such as hepatomegaly, and slight alterations in liver enzymes, are found in approximately 50-75% of patients: it is not possible to exclude that nonsteroidal anti-inXammatory drugs (NSAIDs) may play a signiWcant role in these variations [8, 20, 36] .
Splenomegaly has been found in about 44% of patients [8, 10, [18] [19] [20] : lymphadenopathies also occur frequently, and lymph node biopsies demonstrate benign polyclonal B cells hyperplasia [37] .
Sore throat is a typical sign that can precede fever and other symptoms: it seems to occur early in the disease course in 69% of the patients and it is particularly common in the Wrst month of the disease. Its pathogenesis is still unclear, being attributed both to an inXammation of cricoaritenoid joints and an aseptic non-exudative pharyngitis [38] .
Cardiopulmonary involvement like pleuritis (26.4%) or pericarditis (23.8%) have been observed [8, 10, [18] [19] [20] . Tamponade, myocarditis [39, 40] , pulmonary Wbrosis, pleural eVusions and adult respiratory distress syndrome have also been described [41] .
Haematological complications, like pure red cell aplasia, thrombotic thrombocytopenic purpura and haemolytic uraemic syndrome, have rarely been described: pancytopenia may be due to the haemophagocytic syndrome (HS). It is important to bear in mind that AOSD may begin with an HS [42] . Furthermore, malignant lymphoma should not only be excluded for diagnosis, but they may be added to the large variety of complications associated with this disease [43] . Finally, cases of disseminated intravascular coagulation that have led to death have rarely been described [40] .
The clinical course may be divided into three main patterns, with diVerent prognostic implications:
1. Self-limiting or monophasic pattern is characterised by a single disease episode with systemic symptoms like fever, rash, serositis, and organomegaly. Median time to remission is 9 months, and most patients get remission within 1 year [8] . This clinical pattern has a favourable prognosis and serious complications from disease or therapy are uncommon [8] . 2. Intermittent or polycyclic systemic pattern is marked by recurrent disease Xares, with or without articular symptomatology, interspersed by complete remissions. Subsequent Xares become less severe and can occur many years after the Wrst one [10] . 3. Chronic articular pattern is characterised by a persistent active disease, dominated by the articular manifestations. Arthritis can be severe and lead to joint destruction [8] .
Laboratory
Laboratory test results largely reXect the systemic inXammatory nature of the disease process and none of the Wndings is speciWc for AOSD [24] . An increased sedimentation rate is universal and there is no association with rheumatoid factor (RF) or antinuclear antibody (ANA) [1] . Serum ferritin and its glycosylated fraction are currently assessed as a useful diagnostic and disease activity markers. Ferritin is an acute phase protein closely associated with inXammatory processes, inclusive of the mechanisms underlying oxidative stress. InXammation is linked with increased discharge of ferritin by the histiocyte-macrophage system and from damaged hepatocytes. IL-1 , IL-18, TNF and IL-6 are cytokines that induce the greatest production of ferritin [44] . Serum ferritin levels in AOSD are usually higher than in other autoimmune or inXammatory diseases, and very high levels, between 3,000 and 30,000 ng/ml, are not uncommon (normal range 40-200 ng/ml): even levels higher then 250,000 ng/ml have been reported. A cut oV for ferritin levels of 1,000 ng/ml (Wvefold the upper normal limit) has been used in many studies to be indicative of AOSD [44] . Besides, disease activity seems to be correlated with serum ferritin levels: these ones often normalise during remission, so that they may also be used as a tool to evaluate response to therapy. A retrospective French study with 49 patients employed a threshold of 1,000 ng/ml in serum ferritin as diagnostic marker: a Wvefold increase had 80% sensitivity and 41% speciWcity [45] while, in a Japanese study, sensitivity was 82% and speciWcity 46% [46] .
However, elevated levels of serum ferritin can also be detected in other diseases, such as infections, malignancies, HS and liver diseases like haemochromatosis or Gaucher's disease, so that the usefulness of this marker is limited in clinical practice [44] .
A more speciWc diagnostic tool may be ferritin glycosylated fraction. Glycosylation is a process that protects serum ferritin from proteolytic enzymes. Healthy subjects have 50-80% of serum ferritin glycosylated, whereas this fraction falls to 20-50% in patients with inXammatory diseases. This can be explained both by saturation of glycosylation mechanisms that occurs in inXammatory diseases, and by lower clearance of non-glycosylated proteins by the histiocyte-macrophage system that occurs speciWcally in AOSD [44] . Glycosylated ferritin persists to low levels in both active phases of disease and in remission, so that it cannot be useful in monitoring the response to treatment.
Combining a Wvefold elevation of the serum ferritin concentration with a glycosylate fraction ·20%, diagnostic speciWcity enhances to 93%, while sensitivity drops to 43% [45] .
Patients frequently have a marked leukocytosis, that is the result of a remarkable neutrophilia, probably secondary to bone marrow granulocyte hyperplasia [10, 47] . Fewer than 2% of cases present a diminished white blood cell count, with obvious diagnostic diYculties.
Other haematological alterations include a normocytic normochromic anaemia, with Hb <10 mg/dl, which often associates with increased disease activity, and thrombocytosis [8, 10, 18] .
Liver abnormalities are not uncommon: lactate dehydrogenase, -glutamyltransferase, aspartate aminotransferase, alanine aminotransferase, and bilirubin can increase in 75% of patients with AOSD and frequently rise concomitantly with fever and exacerbations of arthritis [5] .
Diagnosis and classiWcation criteria
Diagnosis is one of exclusion and the diVerential diagnosis may be lengthy (Table 3) . Infectious, neoplastic and autoimmune diseases can mimic the clinical manifestation of AOSD. Cultures and serological tests can be helpful to exclude infections. Moreover, viral syndromes can be excluded if the symptoms remain over 3 months. The clinical and haematological proWle are often suYcient in order to distinguish the disease from lymphomas and leukaemias, but sometimes it may be necessary to resort to bone marrow or lymph node biopsy.
Other disorders frequently confused with the AOSD include reactive arthritis and the other spondyloarthropathies, vasculitides, dermatomyositis, HS, Kikuchi's syndrome, Sweet's syndrome and granulomatous disorders [48] .
There are several sets of classiWcation criteria for AOSD, all developed from retrospective studies. Masson et al. in 1996 published a comparative study about criteria in AOSD: Yamaguchi's criteria [46] (Table 4) were shown to be by far the most sensitive (93.5%), followed by Cush's [49] (80.6%) and Calabro's [50] (80.6%). SpeciWcity could not be evaluated due to lack of a control group [51] . In 2002, Fautrel et al. proposed a new set of classiWcation criteria that took into consideration glycosylated fraction of serum ferritin and deleted exclusion criteria (Table 5 ). This set seems to be promising, because it provided a sensitivity of 80.6% and a speciWcity of 98.5%; however, it has to be validated in diVerent populations before becoming broadly received [20] .
Management
The management of AOSD is Wrstly directed at the acute systemic features of the disease. Therapeutic strategies have been exclusively empirical, with data on treatment eYcacy obtained from case reports, retrospective studies and small case series. The therapy of AOSD includes NSAIDs, glucocorticoids, and other disease modifying anti-rheumatic drugs (DMARDs) to control arthritis and systemic disease [1, 4] .
Non-steroidal anti-inXammatory drugs are traditionally considered Wrst line therapy for musculoskeletal symptoms and fever, but NSAIDs monotherapy is eVective in controlling disease in only 12% of patients [10, 18] . Among NSAIDs, indometacin and naproxen seem to be more eVective in controlling the disease compared with salicylates [8] .
Most patients with AOSD are treated with steroids in the course of the disease, with responses ranging from 76 to 95% [1, 6, 49] . According to the clinical course of AOSD, patients may need increasing steroid treatment: prednisone is required for 57% of patients with the self-limited pattern, for 67% with the intermittent and for 77% with the chronic articular one [10] .
There are no prospective, clinically controlled trials about the use of DMARDs in AOSD. In clinical practice, their use should be proposed for cases in which the combination of NSAIDs and steroids fails or in which a tapering of steroid is necessary [1] . Many drugs have been tried in AOSD, including methotrexate (MTX), cyclosporine A, sulfasalazine, hydroxychloroquine, gold, penicillamine, azathioprine, cyclophosphamide, thalidomide, high-dose intravenous immunoglobulins (IVIg), anti-TNF agents, anakinra and rituximab with overall response across studies at approximately 40% [1] .
Polyarthritis seems to be particularly susceptible to MTX treatment and it resolves completely in many patients, while the results of MTX on systemic manifestations have not yet been well delineated [1] . A small case series of six patients treated with cyclosporine A reported remission in 66% of cases, and improvement in the other 33% [52] .
Treatment with sulfasalazine has been related with high drug toxicity (60 vs. 15% of other drugs) [53] , so this medication should be avoided in AOSD patients.
High-dose IVIg may be employed to achieve remission and control of early disease before the use of steroids [54] .
A prolonged remission of refractory disease was also obtained using CD34-selected autologous peripheral blood stem cell transplantation [55] .
Anti-TNF agents have also been used in uncontrolled studies. In an observational series of 12 patients, addition of etanercept to the pre-study regimens of prednisone, MTX and NSAIDs, leads to an improvement in the number of tender and swollen joints count higher than 63% [56] . Even inXiximab, a monoclonal chimeric anti-TNF antibody, seems to be eVective in AOSD: a European study of eight patients attempted to evaluate the long term outcome of patients treated with inXiximab after the failure of treatments with corticosteroids and DMARDs: the clinical and serological responses improved rapidly in seven out of eight patients, and Wve of them went into long term remission even after discontinuation of therapy [1, 57] .
Interleukin-1 receptor antagonist anakinra has recently emerged as a possible new therapeutic option [58] .
As mentioned above, IL-6 represents an important inXammatory cytokine involved in the pathogenesis of AODS, and it may be a promising target, especially with the development of anti-human IL-6 monoclonal antibody tocilizumab [59] . A case of refractory AOSD successfully treated with rituximab has also been described [60] . 
